Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (271-280 of 338) with videos related to

Pageof 34
Sort By:
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Medicine|August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastomaEudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Clinical and Translational Radiation Oncology|February 9, 2026
Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature reviewLara Caglayan, Oliver Blanck, Judit Boda-Heggemann, et al.
Journal of the National Cancer Institute|November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentVasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular CarcinomaShadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade GliomaEudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Pageof 34

Showing results (271-280 of 338) with videos related to

Sort By:
Pageof 34
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Medicine|August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastomaEudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Clinical and Translational Radiation Oncology|February 9, 2026
Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature reviewLara Caglayan, Oliver Blanck, Judit Boda-Heggemann, et al.
Journal of the National Cancer Institute|November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentVasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular CarcinomaShadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade GliomaEudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Pageof 34